Sanofi's approach to drug discovery and early pipeline development has been changing over the last five years, and its global head of research and chief scientific officer Frank Nestle told In Vivo that some of the investment is beginning to deliver promising new drug candidates.
"It's a science-led organization with a cultural drive, with a play-to-win attitude and a portfolio that is evolving but already...